Details of the Drug

General Information of Drug (ID: DM72JXH)

Drug Name

Losartan

Synonyms

Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan

Indication

Disease Entry	ICD 11	Status	REF
Diabetic kidney disease	GB61.Z	Approved	[1]
Hypertension	BA00-BA04	Approved	[2]
Prediabetes syndrome	N.A.	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypertensive Agents

Affected Organisms

Humans and other mammals

ATC Code

C09CA01: Losartan

C09CA: Angiotensin II receptor blockers (ARBs), plain

C09C: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN

C09: AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

C: CARDIOVASCULAR SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

422.9

Logarithm of the Partition Coefficient (xlogp)

4.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 8.2 mL/min/kg [5]
Elimination: 12% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.8 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.94873 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.01% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.37 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.048 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Capillary fragility increased	Not Available	IL1A	OTPSGILV	[7]
Metabolic disorder	Not Available	CYP2C9	OTGLBN29	[7]
-----------

Chemical Identifiers

Formula: C22H23ClN6O
IUPAC Name: [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
Canonical SMILES: CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
InChI: InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
InChIKey: PSIFNNKUMBGKDQ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3961
ChEBI ID: CHEBI:6541
CAS Number: 114798-26-4
UNII: JMS50MPO89
DrugBank ID: DB00678
TTD ID: D0DD0K
VARIDT ID: DR00429
INTEDE ID: DR0984
ACDINA ID: D00153

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin II receptor type-1 (AGTR1)	TT8DBY3	AGTR1_HUMAN	Antagonist	[8]
HUMAN type-1 angiotensin II receptor (AGTR1)	TTPKMXQ	AGTR1_HUMAN	Blocker	[9]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Peptide transporter 1 (SLC15A1)	DT9G7XN	S15A1_HUMAN	Substrate	[10]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[12]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[13]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[14]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[12]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[15]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[13]
UDP-glucuronosyltransferase 1A10 (UGT1A10)	DEL5N6Y	UD110_HUMAN	Substrate	[13]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2C9 (CYP2C9)	OTGLBN29	CP2C9_HUMAN	Drug Response	[7]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Drug Response	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Diabetic kidney disease

ICD Disease Classification

GB61.Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Angiotensin II receptor type-1 (AGTR1)	DTT	AGTR1	8.95E-01	1.34E-02	0.07
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01
Peptide transporter 1 (SLC15A1)	DTP	PEPT1	4.57E-01	2.15E-02	1.72E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	1.10E-01	-5.91E-02	-3.60E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.82E-04	-1.35E-01	-5.84E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	9.96E-01	-3.17E-03	-1.84E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U2OS	CTRP1	10.4198	12.7394	8.1909	3.6647
-----------

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MCF-7	CTRP1	9.9589	12.2994	8.1133	5.4291
-----------

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SF295	CTRP1	6.7265	7.9639	4.6541	0.406
GaMG	CTRP1	7.3128	8.9001	4.5424	0.4458
LN-229	CTRP1	10.8052	16.9612	6.4515	15.4557
-----------

Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HEC-265	CTRP1	6.6332	7.7048	4.7113	0.2708
HEC-108	CTRP1	6.6413	8.1623	4.5447	0.9574
HEC-6	CTRP1	6.9154	8.3891	4.5733	0.5833
MFE-319	CTRP1	7.0065	12.1707	2.9656	11.4264
HEC-59	CTRP1	7.2261	8.8629	4.5225	0.5648
KLE	CTRP1	7.3937	9.6587	4.2922	1.4531
HEC-251	CTRP1	7.4766	8.8741	4.6109	0.2008
HEC-151	CTRP1	8.6484	9.165	8.578	6.405
JHUEM-2	CTRP1	9.2045	10.7004	8.3561	5.7571
Ishikawa (Heraklio) 02 ER-	CTRP1	6.242	7.3034	4.7037	0.5714
-----------


⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
BL-70	CTRP1	6.355	7.2985	4.7509	0.2927
MC116	CTRP1	6.4074	7.2269	4.7954	0.1414
HT	CTRP1	6.6265	8.1997	4.5236	1.0857
KE-97	CTRP1	7.1642	8.5013	4.6276	0.2691
Ku812	CTRP1	7.3684	9.2281	4.445	0.7645
P3HR-1	CTRP1	7.4884	8.9148	4.6012	0.2172
SU-DHL-5	CTRP1	8.3281	8.9518	8.2878	10.7383
SKM-1	CTRP1	8.3777	9.2188	8.2664	10.5835
U-937	CTRP1	8.4598	11.5438	7.2876	18.4228
WSU-DLCL2	CTRP1	8.5373	8.9345	8.5182	7.591
NU-DUL-1	CTRP1	8.5715	10.407	7.9454	12.2489
PL21	CTRP1	8.7675	9.7141	8.4652	6.6929
KMS-11	CTRP1	8.7846	9.8915	8.3965	7.2114
RPMI-8226	CTRP1	8.8418	10.0904	8.3526	7.3248
EJM	CTRP1	8.9639	10.0218	8.4962	5.4791
THP-1	CTRP1	9.0917	10.8642	8.1835	7.7534
LP-1	CTRP1	9.1192	17.1261	5.0754	28.649
GDM-1	CTRP1	9.226	10.5603	8.4425	4.9016
SU-DHL-4	CTRP1	9.3012	11.0143	8.2751	6.122
OCI-AML-3	CTRP1	9.3454	10.4462	8.5871	3.2034
AMO1	CTRP1	9.5932	11.2147	8.3872	4.1671
NOMO-1	CTRP1	9.7545	11.5188	8.3491	4.0254
MOLM-16	CTRP1	9.9991	11.8206	8.3607	3.3019
OCI-Ly10	CTRP1	11.0962	18.1866	6.0612	16.9411
-----------


⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
VMRC-RCW	CTRP1	6.6524	8.9076	4.2442	2.8119
RCC10RGB	CTRP1	10.9841	12.3347	8.6195	0.375
-----------

Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SW48	CTRP1	6.0943	8.8243	3.9533	6.3777
DLD-1	CTRP1	6.4579	7.6398	4.6664	0.55
LS411N	CTRP1	6.5558	7.6811	4.6903	0.3832
LS513	CTRP1	6.674	8.5426	4.408	1.6941
SK-CO-1	CTRP1	6.7255	8.5349	4.4354	1.4596
COLO205	CTRP1	6.922	8.5247	4.5255	0.78
C2BBe1	CTRP1	7.0233	8.7695	4.4752	0.9199
SNU-C2A	CTRP1	7.2947	9.991	4.1129	2.6181
GP2d	CTRP1	7.7198	9.3034	4.5504	0.2534
SW403	CTRP1	7.9564	9.6224	4.5251	0.2345
SW480	CTRP1	8.3536	10.2625	7.8014	14.6271
SW620	CTRP1	8.6106	9.1653	8.537	6.9682
LS123	CTRP1	8.9257	10.4375	8.2556	7.8102
LS180	CTRP1	9.1488	10.2184	8.5523	4.2072
HCT 116	CTRP1	9.164	10.3001	8.5236	4.4072
MDST8	CTRP1	9.6946	11.642	8.251	5.0301
HT-55	CTRP1	9.8472	11.1817	8.5602	2.0948
COLO 678	CTRP1	9.9652	12.2804	8.1263	5.3034
RCM-1 [Human ESC]	CTRP1	10.1132	11.911	8.3861	2.845
HT115	CTRP1	10.3719	11.6445	8.6281	0.816
COLO 320	CTRP1	10.3859	12.8961	8.1009	4.4328
SNU-C4	CTRP1	10.4305	11.3024	8.7776	0.1761
KM12	CTRP1	10.5052	11.878	8.5957	0.8409
SNU-175	CTRP1	10.5801	12.2003	8.5023	1.26
SNU-C5	CTRP1	10.6374	12.2128	8.5233	1.0748
HT-29	CTRP1	10.6458	11.5883	8.7563	0.1498
SNU-61	CTRP1	10.6744	12.429	8.4543	1.4164
RKO	CTRP1	10.7675	14.5955	7.5518	7.7595
CL-34	CTRP1	10.8094	12.2313	8.5891	0.5983
NCI-H508	CTRP1	10.8418	12.3656	8.5522	0.7299
SW948	CTRP1	10.8495	12.1751	8.6254	0.432
SNU-81	CTRP1	10.851	12.4241	8.5339	0.8044
HCT 8	CTRP1	10.8995	12.0423	8.6909	0.2126
SNU-1040	CTRP1	10.9729	12.4636	8.5687	0.5605
LoVo	CTRP1	11.0943	13.0976	8.3793	1.3265
CL-40	CTRP1	11.2068	12.589	8.6126	0.2908
CW-2	CTRP1	11.4865	13.1621	8.5147	0.4423
-----------


⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHH-6	CTRP1	6.1424	7.0883	4.7435	0.4773
SNU-449	CTRP1	6.99	8.9293	4.3989	1.3397
SNU-398	CTRP1	8.627	9.732	8.3183	8.7075
Hep-G2	CTRP1	11.0833	12.5976	8.5631	0.5086
-----------

Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SHP-77	CTRP1	6.3188	9.7239	3.6743	8.0195
BEN	CTRP1	6.3291	7.7026	4.5859	1.0997
VMRC-LCD	CTRP1	6.7162	8.3615	4.5	1.1099
LCLC-103H	CTRP1	6.719	7.9258	4.6649	0.373
NCI-H1048	CTRP1	6.7375	8.5407	4.4386	1.4255
NCI-H2029	CTRP1	6.7431	8.5519	4.4367	1.4294
DV-90	CTRP1	6.7508	9.2871	4.1326	3.417
NCI-H1573	CTRP1	6.8164	8.6957	4.4129	1.4722
COR-L88	CTRP1	6.9052	8.6719	4.4621	1.1011
NCI-H1930	CTRP1	6.9067	8.4314	4.5541	0.6682
NCI-H1299	CTRP1	6.9095	9.5379	4.1087	3.2874
NCI-H1435	CTRP1	7.0137	8.7972	4.4605	0.9988
Lu-99	CTRP1	7.0145	8.4277	4.5979	0.429
LC-1/sq-SF	CTRP1	7.0623	8.5084	4.5872	0.4376
NCI-H810	CTRP1	7.077	8.4431	4.6159	0.3392
NCI-H1793	CTRP1	7.1267	8.6264	4.5695	0.4601
HCC78	CTRP1	7.1317	8.8952	4.4728	0.835
NCI-H2009	CTRP1	7.1612	8.9131	4.4781	0.7876
DMS 273	CTRP1	7.1879	8.8015	4.5299	0.5623
Lu-65	CTRP1	7.1909	8.8084	4.5285	0.5654
NCI-H1944	CTRP1	7.2075	9.358	4.3275	1.4744
HCC33	CTRP1	7.2158	8.7183	4.5705	0.4082
EBC-1	CTRP1	7.2204	9.9674	4.086	2.9058
RERF-LC-KJ	CTRP1	7.2777	8.8588	4.5438	0.4602
NCI-H2126	CTRP1	7.2891	8.3952	4.707	0.0851
NCI-H1915	CTRP1	7.2908	8.7742	4.5786	0.3473
COR-L279	CTRP1	7.297	8.6236	4.633	0.2092
Calu-6	CTRP1	7.304	8.7024	4.6085	0.2632
NCI-H1373	CTRP1	7.3103	8.9403	4.527	0.4976
Calu-3	CTRP1	7.3186	8.9105	4.5408	0.4477
COLO 668	CTRP1	7.3304	9.1095	4.4735	0.6791
ChaGo-K-1	CTRP1	7.3506	9.3248	4.4017	0.9639
NCI-H1975	CTRP1	7.3694	9.0655	4.5047	0.5393
NCI-H1437	CTRP1	7.3849	9.2908	4.4284	0.8203
HCC44	CTRP1	7.41	9.2754	4.4442	0.7373
LXF 289	CTRP1	7.4124	9.6427	4.3065	1.3597
EPLC-272H	CTRP1	7.4334	9.5759	4.3412	1.1687
NCI-H82	CTRP1	7.4396	8.8915	4.5919	0.2537
NCI-H661	CTRP1	7.4557	9.7059	4.3009	1.3434
NCI-H1666	CTRP1	7.5324	9.8259	4.2877	1.3311
KNS-62	CTRP1	7.5616	9.0118	4.594	0.2102
NCI-H522	CTRP1	7.6164	9.0765	4.5912	0.2002
NCI-H2286	CTRP1	7.6219	9.2657	4.5283	0.3419
NCI-H358	CTRP1	7.643	9.5626	4.4309	0.6315
HARA [Human squamous cell lung carcinoma]	CTRP1	7.6648	9.3183	4.5256	0.3317
NCI-H727	CTRP1	7.6675	9.818	4.347	0.9396
NCI-H650	CTRP1	7.7699	9.2147	4.5978	0.1509
NCI-H23	CTRP1	7.7735	9.5669	4.4786	0.4115
NCI-H1568	CTRP1	7.8465	9.4516	4.5446	0.2272
LCLC-97TM1	CTRP1	7.8923	9.8601	4.4194	0.5294
NCI-H1792	CTRP1	8.063	9.7412	4.522	0.2116
NCI-H1105	CTRP1	8.1564	9.2644	8.011	14.0056
A-549	CTRP1	8.2415	9.8515	4.5463	0.1351
NCI-H1355	CTRP1	8.2546	10.3471	4.3823	0.4662
NCI-H2405	CTRP1	8.2793	10.1612	4.4553	0.2815
NCI-H1963	CTRP1	8.5145	9.5766	8.2729	9.716
COR-L51	CTRP1	8.5822	10.6741	7.8262	13.24
NCI-H1694	CTRP1	8.6767	9.5763	8.4392	7.3991
HCC2108	CTRP1	8.7138	9.4957	8.513	6.5635
HCC1195	CTRP1	8.8085	9.6792	8.5215	5.9906
NCI-H2081	CTRP1	8.9154	10.0036	8.4622	6.0032
NCI-H1781	CTRP1	8.919	9.766	8.5829	4.907
NCI-H1876	CTRP1	8.9852	10.0653	8.493	5.4143
HCC1359	CTRP1	9.0427	9.9513	8.5991	4.212
NCI-H2141	CTRP1	9.1313	10.3041	8.4955	4.7858
NCI-H841	CTRP1	9.1924	10.4704	8.4611	4.8603
HCC4006	CTRP1	9.2325	11.1599	8.1494	7.5034
SCLC-21H	CTRP1	9.2448	10.7979	8.339	5.7583
COLO 699	CTRP1	9.2951	10.8189	8.3671	5.3226
T3M-10	CTRP1	9.3814	11.0208	8.332	5.3311
NCI-H2110	CTRP1	9.477	11.3627	8.2341	5.8698
NCI-H2342	CTRP1	9.5089	11.2516	8.3112	5.0883
NCI-H1836	CTRP1	9.5148	11.622	8.1346	6.6178
NCI-H2030	CTRP1	9.6363	11.2191	8.4138	3.8137
HCC2935	CTRP1	9.6632	11.3523	8.3683	4.1223
NCI-H2122	CTRP1	9.7258	11.0258	8.56	2.3717
HCC1833	CTRP1	9.7268	11.5461	8.3182	4.3639
NCI-H441	CTRP1	9.7725	12.1603	8.0551	6.4731
CAL-12T	CTRP1	9.8172	11.4705	8.4112	3.3445
COR-L23	CTRP1	9.8509	11.0744	8.6095	1.7183
SK-LU-1	CTRP1	10.0184	11.991	8.2943	3.7846
NCI-H2023	CTRP1	10.0639	11.8771	8.373	3.0546
HCC827	CTRP1	10.1516	11.7629	8.4723	2.129
HCC15	CTRP1	10.3879	12.5807	8.2434	3.3372
NCI-H2172	CTRP1	10.4472	12.0709	8.4922	1.501
NCI-H1755	CTRP1	10.5403	12.3694	8.4145	1.8535
NCI-H596	CTRP1	10.6524	12.1034	8.5722	0.809
NCI-H460	CTRP1	10.7131	11.7844	8.7128	0.2302
NCI-H3255	CTRP1	10.9527	12.5846	8.5157	0.7976
Sq-1	CTRP1	10.9606	12.1309	8.6823	0.2111
NCI-H2073	CTRP1	11.5894	13.0876	8.578	0.2353
-----------


⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KYSE-450	CTRP1	7.1089	8.731	4.5245	0.6366
KYSE-410	CTRP1	7.2057	9.4851	4.2763	1.7596
KYSE-140	CTRP1	8.1207	10.162	4.3979	0.4824
-----------

Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COV318	CTRP1	6.4939	7.399	4.7671	0.1779
OVMANA	CTRP1	7.1162	8.8194	4.4948	0.7529
HEY A8	CTRP1	7.3904	9.1979	4.4649	0.6709
EFO-21	CTRP1	7.5207	8.9112	4.6138	0.1829
JHOS-4	CTRP1	7.7272	9.4904	4.4884	0.405
SK-OV-3	CTRP1	7.9987	9.2694	4.6562	0.0511
A2780	CTRP1	8.5877	9.4274	8.4122	8.1275
OVK18	CTRP1	8.666	9.8045	8.3234	8.4568
OVCAR-4	CTRP1	8.7947	10.2471	8.2325	8.619
TYK-nu	CTRP1	8.812	9.5053	8.607	5.2249
JHOC-5	CTRP1	8.8306	9.3189	8.7106	4.2326
OVCAR-8	CTRP1	8.9063	9.8206	8.5445	5.3092
OV-90	CTRP1	9.0223	9.9131	8.6009	4.2819
JHOM-1	CTRP1	9.0271	9.8465	8.6383	3.9242
EFO-27	CTRP1	9.2461	10.7948	8.3416	5.7307
RMG-I	CTRP1	9.288	11.6582	7.9449	9.1132
RMUG-S	CTRP1	9.3193	12.1699	7.7147	11.0114
OVKATE	CTRP1	9.3925	11.0743	8.3139	5.4531
COV434	CTRP1	9.5864	12.4819	7.7646	9.5936
IGROV-1	CTRP1	9.8461	13.8726	7.2724	12.7514
OAW42	CTRP1	9.9171	11.078	8.643	1.3573
SNU-840	CTRP1	10.1837	12.0043	8.3843	2.7096
COV644	CTRP1	10.9914	12.5143	8.5574	0.5913
Caov-3	CTRP1	11.0342	12.7066	8.5034	0.7825
COV362	CTRP1	11.0837	12.4244	8.625	0.31
OV7	CTRP1	11.0985	13.3803	8.2687	1.9452
-----------


⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CFPAC-1	CTRP1	6.7325	9.8954	3.852	5.5449
HPAC	CTRP1	6.8943	8.4137	4.5556	0.6717
Panc 10.05	CTRP1	6.9169	8.9601	4.3533	1.688
PaTu 8902	CTRP1	6.9961	8.2973	4.6373	0.3152
QGP-1	CTRP1	7.1152	8.4545	4.626	0.2934
Capan-2	CTRP1	7.2148	9.2246	4.3826	1.1815
KP-3	CTRP1	7.3457	10.1307	4.0801	2.7472
Panc 03.27	CTRP1	7.3546	8.7359	4.615	0.23
SUIT-2	CTRP1	7.3964	8.9772	4.5463	0.3914
HuP-T4	CTRP1	7.7281	9.7338	4.4019	0.682
-----------


⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H2052	CTRP1	6.9253	9.2361	4.2443	2.3497
MSTO-211H	CTRP1	7.2327	9.6396	4.2268	2.0118
NCI-H28	CTRP1	7.4686	9.549	4.3662	1.0209
-----------

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
PaCa-3	CTRP1	6.7573	8.4077	4.5001	1.0637
-----------

Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Hs 936.T	CTRP1	6.7344	8.021	4.6365	0.4653
COLO 741	CTRP1	7.0643	9.134	4.3515	1.5114
Hs 852.T	CTRP1	7.1342	8.7962	4.5106	0.6737
G-361	CTRP1	7.3474	8.7576	4.605	0.2556
Hs 944.T	CTRP1	7.4093	9.0386	4.5295	0.436
SK-MEL-1	CTRP1	9.1564	14.2435	6.5474	20.7293
SK-MEL-5	CTRP1	9.4251	10.5599	8.5872	2.9531
SK-MEL-28	CTRP1	9.7514	10.6231	8.7507	0.9118
A-375	CTRP1	11.0965	12.3815	8.6446	0.2525
-----------


⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
G-401	CTRP1	7.8769	10.3296	4.2413	1.2264
RKN	CTRP1	8.7913	9.344	8.6593	4.8881
HT-1080	CTRP1	8.9347	9.6711	8.644	4.2868
-----------

Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH-10-TC	CTRP1	6.8255	7.9489	4.6965	0.2271
Fu97	CTRP1	7.2411	8.6391	4.6076	0.2898
NUGC-4	CTRP1	7.4355	9.0725	4.5273	0.4294
MKN7	CTRP1	7.4553	9.2107	4.4855	0.5546
MKN74	CTRP1	7.6747	9.9183	4.3124	1.0832
AGS	CTRP1	10.9703	12.1846	8.6672	0.2447
SNG-M	CTRP1	7.6125	9.8774	4.302	1.1859
-----------


⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HSC-2	CTRP1	7.4591	8.9648	4.5737	0.2904
SCC-9	CTRP1	9.5376	11.4409	8.2394	5.6225
-----------

Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HT-1376	CTRP1	6.734	11.5372	3.0869	11.3338
RT-4	CTRP1	7.2117	9.6298	4.2209	2.0751
5637	CTRP1	7.238	9.6571	4.2222	2.0318
UM-UC-3	CTRP1	7.2584	8.7014	4.5922	0.3238
KMBC-2	CTRP1	7.6959	9.5428	4.4582	0.5101
-----------

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Losartan

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Aliskiren	DM1BV7W	Major	Increased risk of hyperkalemia by the combination of Losartan and Aliskiren.	Hypertension [BA00-BA04]	[16]
Moexipril	DM26E4B	Major	Increased risk of hyperkalemia by the combination of Losartan and Moexipril.	Hypertension [BA00-BA04]	[17]
Captopril	DM458UM	Major	Increased risk of hyperkalemia by the combination of Losartan and Captopril.	Hypertension [BA00-BA04]	[17]
Perindopril	DMOPZDT	Major	Increased risk of hyperkalemia by the combination of Losartan and Perindopril.	Hypertension [BA00-BA04]	[17]
Quinapril	DMR8H31	Major	Increased risk of hyperkalemia by the combination of Losartan and Quinapril.	Hypertension [BA00-BA04]	[17]
Lisinopril	DMUOK4C	Major	Increased risk of hyperkalemia by the combination of Losartan and Lisinopril.	Hypertension [BA00-BA04]	[17]
-----------


⏷ Show the Full List of 6 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Losartan (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Losartan caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[18]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Losartan and Insulin-aspart.	Acute diabete complication [5A2Y]	[19]
Methylphenobarbital	DMDSWAG	Minor	Increased metabolism of Losartan caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[20]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Losartan caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[21]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of Losartan caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[22]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Losartan and Cariprazine.	Bipolar disorder [6A60]	[23]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Losartan caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[24]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Losartan and Olopatadine.	Conjunctiva disorder [9A60]	[25]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Losartan and Drospirenone.	Contraceptive management [QA21]	[26]
Ardeparin	DMYRX8B	Moderate	Increased risk of hyperkalemia by the combination of Losartan and Ardeparin.	Coronary thrombosis [BA43]	[17]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Losartan caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[27]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Losartan caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[28]
MK-8228	DMOB58Q	Moderate	Increased metabolism of Losartan caused by MK-8228 mediated induction of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[29]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Losartan and Selegiline.	Depression [6A70-6A7Z]	[30]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Losartan and Isocarboxazid.	Depression [6A70-6A7Z]	[30]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Losartan and Tranylcypromine.	Depression [6A70-6A7Z]	[30]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Losartan and OPC-34712.	Depression [6A70-6A7Z]	[23]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Losartan and Phenelzine.	Depression [6A70-6A7Z]	[30]
Primidone	DM0WX6I	Minor	Increased metabolism of Losartan caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Phenobarbital	DMXZOCG	Minor	Increased metabolism of Losartan caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Losartan caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[31]
Ketoconazole	DMPZI3Q	Minor	Decreased metabolism of Losartan caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[22]
Eplerenone	DMF0NQR	Moderate	Increased risk of hyperkalemia by the combination of Losartan and Eplerenone.	Heart failure [BD10-BD1Z]	[32]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Losartan caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[33]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Losartan caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[34]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Losartan and Procarbazine.	Hodgkin lymphoma [2B30]	[30]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Losartan caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Losartan caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[36]
Potassium chloride	DMMTAJC	Major	Increased risk of hyperkalemia by the combination of Losartan and Potassium chloride.	Hypo-kalaemia [5C77]	[37]
Tolvaptan	DMIWFRL	Moderate	Increased risk of hyperkalemia by the combination of Losartan and Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[38]
Amobarbital	DM0GQ8N	Minor	Increased metabolism of Losartan caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[20]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Losartan and Propiomazine.	Insomnia [7A00-7A0Z]	[23]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Losartan and ITI-007.	Insomnia [7A00-7A0Z]	[23]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Losartan and Porfimer Sodium.	Lung cancer [2C25]	[39]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Losartan caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[36]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Losartan caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[40]
Ozanimod	DMT6AM2	Moderate	Additive hypotensive effects by the combination of Losartan and Ozanimod.	Multiple sclerosis [8A40]	[30]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Losartan and Promethazine.	Nausea/vomiting [MD90]	[23]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Losartan caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[41]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Losartan and Safinamide.	Parkinsonism [8A00]	[30]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Losartan and Rasagiline.	Parkinsonism [8A00]	[30]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Losartan caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[42]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Losartan caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[43]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Losartan caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[44]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Losartan and Levomepromazine.	Psychotic disorder [6A20-6A25]	[23]
Leflunomide	DMR8ONJ	Moderate	Decreased metabolism of Losartan caused by Leflunomide mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[45]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Losartan and Quetiapine.	Schizophrenia [6A20]	[23]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Losartan and Mesoridazine.	Schizophrenia [6A20]	[23]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Losartan and Thioridazine.	Schizophrenia [6A20]	[23]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Losartan and Aripiprazole.	Schizophrenia [6A20]	[23]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Losartan and Iloperidone.	Schizophrenia [6A20]	[23]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Losartan and Paliperidone.	Schizophrenia [6A20]	[23]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Losartan and Molindone.	Schizophrenia [6A20]	[23]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Losartan and Thiothixene.	Schizophrenia [6A20]	[23]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Losartan and Trifluoperazine.	Schizophrenia [6A20]	[23]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Losartan and Risperidone.	Schizophrenia [6A20]	[23]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Losartan and Amisulpride.	Schizophrenia [6A20]	[23]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Losartan and Asenapine.	Schizophrenia [6A20]	[23]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Losartan caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[36]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Losartan caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[46]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Losartan and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[47]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Losartan and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[47]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Losartan and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[23]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Losartan and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[48]
-----------


⏷ Show the Full List of 64 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Methyl chloride	E00114	6327	Other agent
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000	E00654	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Water	E00035	962	Solvent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 29 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Losartan 100 mg tablet	100 mg	Oral Tablet	Oral
Losartan 25 mg tablet	25 mg	Oral Tablet	Oral
Losartan 50 mg tablet	50 mg	Oral Tablet	Oral
Losartan Potassium 25mg tablet	25mg	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Losartan FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 590).
3	ClinicalTrials.gov (NCT04343001) Coronavirus Response - Active Support for Hospitalised Covid-19 Patients. U.S. National Institutes of Health.
4	BDDCS applied to over 900 drugs
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41.
9	Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3.
10	High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
11	Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and caco-2 cell monolayers. Br J Pharmacol. 2000 Mar;129(6):1235-43.
12	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14	The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol. 2008 Sep 15;76(6):763-72.
15	Drug-drug interaction between losartan and paclitaxel in human liver microsomes with different CYP2C8 genotypes. Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):493-8.
16	Health Canada "Potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes treated with aliskiren (RASILEZ) or aliskiren/hydrochlorothiazide (RASILEZ HCT)." .
17	Product Information. Diovan (valsartan). Novartis Pharmaceuticals, East Hanover, NJ.
18	Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
19	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
20	Goldberg MR, Lo MW, Deutsch PJ, Wilson SE, Mcwilliams EJ, Mccrea JB "Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite e-3174." Clin Pharmacol Ther 59 (1996): 268-74. [PMID: 8653989]
21	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
22	Product Information. Cozaar (losartan). Merck & Co, Inc, West Point, PA.
23	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
24	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
25	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
26	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
27	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
28	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
29	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
30	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
31	Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
32	Product Information. Inspra (eplerenone). Searle, Chicago, IL.
33	Product Information. Cozaar (losartan). Merck &amp Co, Inc, West Point, PA.
34	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
35	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
36	Cerner Multum, Inc. "Australian Product Information.".
37	Walmsley RN, White GH, Cain M, McCarthy PJ, Booth J "Hyperkalemia in the elderly." Clin Chem 30 (1984): 1409-12. [PMID: 6744599]
38	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
39	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
40	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
41	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
42	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
43	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
44	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
45	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
46	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
47	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
48	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.